Citius Oncology, Inc. (CTOR)

Citius Oncology Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022
Prepaid Expenses	8.91	7.73	2.69
Total Current Assets	8.91	7.73	2.69
Long-Term Deferred Charges	40	40	40
Total Assets	48.91	47.73	42.69
Accounts Payable	0.5	1.29	0.09
Accrued Expenses	27.12	19.76	5.75
Total Current Liabilities	27.62	21.05	5.85
Long-Term Deferred Tax Liabilities	1.44	1.15	0.58
Total Liabilities	29.06	22.2	6.42
Common Stock	0.01	0.01	0.01
Additional Paid-In Capital	47.53	43.66	41.69
Retained Earnings	-27.69	-18.13	-5.43
Shareholders' Equity	19.85	25.54	36.27
Total Liabilities & Equity	48.91	47.73	42.69
Filing Date Shares Outstanding	67.5	67.5	67.5
Total Common Shares Outstanding	67.5	67.5	67.5
Working Capital	-18.71	-13.31	-3.16
Book Value Per Share	0.29	0.38	0.54
Tangible Book Value	19.85	25.54	36.27
Tangible Book Value Per Share	0.29	0.38	0.54

Source: S&P Capital IQ. Standard template. Financial Sources.